کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3978729 | 1257296 | 2013 | 4 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Métastases cérébrales des cancers bronchiques non à petites cellules : traitement systémique
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
تومور شناسی
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
Chemotherapy, as all systemic treatments, is generally effective in brain metastases because the brain blood barrier (BBB) does not affect treatment's diffusion. Platinum-based chemotherapy provides response rates ranging from 23 to 50% for brain metastases. Anti-EGFR therapies are effective mostly when a somatic EGFR activating mutation is detected, or in selected population (adenocarcinoma, Asian population, never-smokers and women): response rate ranges from 38 to 69.6%. Bevacizumab is now allowed for non-small cell lung cancer (NSCLC) patients with brain metastases and non-squamous histology. The presence of untreated brain metastases may not influence its efficacy combined with paclitaxel-carboplatin. The best sequence for multimodality management of brain metastases has to be established but upfront systemic treatments in patients with asymptomatic brain metastases is a valid option.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Bulletin du Cancer - Volume 100, Issue 1, January 2013, Pages 95-98
Journal: Bulletin du Cancer - Volume 100, Issue 1, January 2013, Pages 95-98
نویسندگان
Marie Chaubet-Houdu, Benjamin Besse,